Influenza virus vaccine trivalent - Protein Sciences Corporation

Drug Profile

Influenza virus vaccine trivalent - Protein Sciences Corporation

Alternative Names: ASP-7374; FluBlok; Seasonal influenza vaccine - Protein Sciences Corporation; Trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine (FluBlok); UMN-05; UMN-0502

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Protein Sciences Corporation
  • Developer Astellas Pharma; Ildong Pharmaceutical; Laboratorios Liomont; Protein Sciences Corporation; UMN Pharma
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 22 Feb 2017 Launched for Influenza virus infections (Prevention) in Mongolia (IM)
  • 10 Jan 2017 UMN Pharma terminates its licence for Influenza virus vaccine trivalent in Japan
  • 14 Oct 2016 Launched for Influenza virus infections (Prevention, In adults) in Mexico (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top